Savient Pharmaceuticals (SVNT) Posts Q4 Loss of 44c/Sh., Misses Views
Get Alerts SVNT Hot Sheet
Join SI Premium – FREE
Savient Pharmaceuticals (NASDAQ: SVNT) reported Q4 EPS of ($0.44), $0.06 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $3.71 million versus the consensus estimate of $3.51 million.
For earnings history and earnings-related data on Savient Pharmaceuticals (SVNT) click here.
For earnings history and earnings-related data on Savient Pharmaceuticals (SVNT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies sees a buying opportunity in this S&P 500 sector
- Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
- SanDisk unveils long-term growth strategy at 2026 Investor Day; Shares surge 12%
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share